These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

678 related articles for article (PubMed ID: 19139383)

  • 1. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1).
    Jaff MR; Dale RA; Creager MA; Lipicky RJ; Constant J; Campbell LA; Hiatt WR
    Circulation; 2009 Jan; 119(3):452-8. PubMed ID: 19139383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secondary prevention of atherosclerosis through chlamydia pneumoniae eradication (SPACE Trial): a randomised clinical trial in patients with peripheral arterial disease.
    Vainas T; Stassen FR; Schurink GW; Tordoir JH; Welten RJ; van den Akker LH; Kurvers HA; Bruggeman CA; Kitslaar PJ
    Eur J Vasc Endovasc Surg; 2005 Apr; 29(4):403-11. PubMed ID: 15749042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease.
    Grossman PM; Mendelsohn F; Henry TD; Hermiller JB; Litt M; Saucedo JF; Weiss RJ; Kandzari DE; Kleiman N; Anderson RD; Gottlieb D; Karlsberg R; Snell J; Rocha-Singh K
    Am Heart J; 2007 May; 153(5):874-80. PubMed ID: 17452167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.
    Mohler ER; Hiatt WR; Creager MA
    Circulation; 2003 Sep; 108(12):1481-6. PubMed ID: 12952839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease.
    Brass EP; Anthony R; Cobb FR; Koda I; Jiao J; Hiatt WR
    J Am Coll Cardiol; 2006 Dec; 48(12):2539-45. PubMed ID: 17174195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.
    Rajagopalan S; Mohler ER; Lederman RJ; Mendelsohn FO; Saucedo JF; Goldman CK; Blebea J; Macko J; Kessler PD; Rasmussen HS; Annex BH
    Circulation; 2003 Oct; 108(16):1933-8. PubMed ID: 14504183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PoleStriding exercise and vitamin E for management of peripheral vascular disease.
    Collins EG; Edwin Langbein W; Orebaugh C; Bammert C; Hanson K; Reda D; Edwards LC; Littooy FN
    Med Sci Sports Exerc; 2003 Mar; 35(3):384-93. PubMed ID: 12618567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication.
    Creager MA; Olin JW; Belch JJ; Moneta GL; Henry TD; Rajagopalan S; Annex BH; Hiatt WR
    Circulation; 2011 Oct; 124(16):1765-73. PubMed ID: 21947297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life and exercise performance after aortoiliac stent placement for claudication.
    Murphy TP; Soares GM; Kim HM; Ahn SH; Haas RA
    J Vasc Interv Radiol; 2005 Jul; 16(7):947-53; quiz 954. PubMed ID: 16002502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifalazil and other benzoxazinorifamycins in the treatment of chlamydia-based persistent infections.
    Rothstein DM; van Duzer J; Sternlicht A; Gilman SC
    Arch Pharm (Weinheim); 2007 Oct; 340(10):517-29. PubMed ID: 17912677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of intermittent claudication with mesoglycan--a placebo-controlled, double-blind study.
    Nenci GG; Gresele P; Ferrari G; Santoro L; Gianese F;
    Thromb Haemost; 2001 Nov; 86(5):1181-7. PubMed ID: 11816704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional Angiogenesis with Vascular Endothelial Growth Factor (VEGF) in peripheral arterial disease: Design of the RAVE trial.
    Rajagopalan S; Mohler E; Lederman RJ; Saucedo J; Mendelsohn FO; Olin J; Blebea J; Goldman C; Trachtenberg JD; Pressler M; Rasmussen H; Annex BH; Hirsch AT;
    Am Heart J; 2003 Jun; 145(6):1114-8. PubMed ID: 12796772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of iloprost in patients with intermittent claudication.
    Creager MA; Pande RL; Hiatt WR
    Vasc Med; 2008 Feb; 13(1):5-13. PubMed ID: 18372433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.
    ; Leizorovicz A; Becker F
    Circulation; 2008 Feb; 117(6):816-22. PubMed ID: 18212283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Oslo balloon angioplasty versus conservative treatment study (OBACT)--the 2-years results of a single centre, prospective, randomised study in patients with intermittent claudication.
    Nylaende M; Abdelnoor M; Stranden E; Morken B; Sandbaek G; Risum Ø; Jørgensen JJ; Lindahl AK; Arnesen H; Seljeflot I; Kroese AJ
    Eur J Vasc Endovasc Surg; 2007 Jan; 33(1):3-12. PubMed ID: 17055756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized controlled trial of supervised exercise to evaluate changes in cardiac function in patients with peripheral atherosclerotic disease.
    Hodges LD; Sandercock GR; Das SK; Brodie DA
    Clin Physiol Funct Imaging; 2008 Jan; 28(1):32-7. PubMed ID: 18005078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute impairment of the endothelial function by maximal treadmill exercise in patients with intermittent claudication, and its improvement after supervised physical training.
    Andreozzi GM; Leone A; Laudani R; Deinite G; Martini R
    Int Angiol; 2007 Mar; 26(1):12-7. PubMed ID: 17353883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect on walking distance and atherosclerosis progression of a nitric oxide-donating agent in intermittent claudication.
    Gresele P; Migliacci R; Arosio E; Bonizzoni E; Minuz P; Violi F;
    J Vasc Surg; 2012 Dec; 56(6):1622-8, 1628.e1-5. PubMed ID: 22963812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of the walking ability in intermittent claudication due to superficial femoral artery occlusion with supervised exercise and pneumatic foot and calf compression: a randomised controlled trial.
    Kakkos SK; Geroulakos G; Nicolaides AN
    Eur J Vasc Endovasc Surg; 2005 Aug; 30(2):164-75. PubMed ID: 15890545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparan sulfate in the treatment of intermittent claudication: results of a randomized, double-blind, placebo-controlled multicenter trial.
    Messa GL; Gelso E
    Drugs Exp Clin Res; 2002; 28(1):37-48. PubMed ID: 12073766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.